Who Paid My Doc
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302
ClinicalTrials.gov NCT03259308
Research payments
$673,268
Through program year 2019, $673,268 in research payments was reported against A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302, across 188 payments, paid by Shire North American Group Inc.
- Paid by
- Shire North American Group Inc
- ClinicalTrials.gov
- NCT03259308
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $673,268 | 188 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Melvin Heyman San Francisco, CA Named on 13 payments
- Albert Diaz-Ordaz Orchard Park, NY Named on 13 payments
- Matthew Smith Oakbrook Terrace, IL Named on 10 payments
- Mark Fleisher Jacksonville, FL Named on 8 payments
- James Maher Houston, TX Named on 8 payments
- Jeff Bullock San Antonio, TX Named on 7 payments
- Kevin Merkes Poway, CA Named on 6 payments
- Mark Kogan San Pablo, CA Named on 6 payments
- Fred Rosenberg Gurnee, IL Named on 6 payments
- George Christophi Saint Louis, MO Named on 5 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.